Multiple comparisons by Tukey’s post hoc testing revealed that the HER2-positive group exhibited a higher fluorescence signal compared to both the HER2-negative and non-tumor groups (p < 0.05), and there was no statistical difference between the HER2-negative and non-tumor groups (p > 0.05). Here, ERBB2 is linked to neoplasm.